This site is intended for health professionals only
Saturday 23 February 2019
Share |

Topic: Personalised medicine

September 28, 2015
Perjeta (pertuzumab) regimen nearly doubled number of women whose tumours are eradicated versus standard treatment

Over 1800 women per year in the UK with an aggressive type of breast cancer could benefit from Perjeta (pertuzumab) as a targeted neo-adjuvant (pre-surgery) treatment for HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. Perjeta is licensed for use in combination with current treatment Herceptin® (trastuzumab) and chemotherapy.
 

May 12, 2014
Over half of the active products in the global industry research pipeline are personalised medicines, and the UK healthcare system is at risk of failing to adapt to this new challenge, a new report published today reveals.

Over half of the active products in the global industry research pipeline are personalised medicines, and the UK healthcare system is at risk of failing to adapt to this new challenge, a new report published today reveals.

May 9, 2014

The results of a number of exciting studies in leukaemias will be presented at the 19th Congress of the European Hematology Association (EHA).

Leukaemias are life-threatening diseases that can devastate the lives of patients and their families. Great progress has been made in treatments to improve the survival of these otherwise invariably fatal conditions. Major advances in the understanding of leukaemia genetics for genome sequencing of individual patients has taken scientists one step further towards realising personalised medicine for many patients.

April 2, 2013
Pharmacists could become key players in recommending pharmacogenetic testing and interpreting test results, and it is essential that pharmacy schools start training programmes in the management, application and delivery of this information

teaser

October 17, 2012
The recent development of agents such as vemurafenib (Zelboraf) is offering an alternative to conventional chemotherapeutic agents and personalising the face of treatment for metastatic melanoma

teaser

September 6, 2012
A follow-up subanalysis of the most influential atrial-fibrillation (AF) trial of dabigatran etexilate (Pradaxa, Boehringer Ingelheim), an oral antithrombin alternative to warfarin, identified a common gene variant that seems to influence the bleeding risk associated with the drug but not its antithrombotic efficacy [1].

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine